AC0058TA / Sorrento - LARVOL DELTA

Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics (GlobeNewswire) - "Sorrento Therapeutics, Inc....today announced the signing of a merger agreement pursuant to which Sorrento will acquire ACEA Therapeutics, Inc. ('ACEA'). The acquisition will include late clinical stage drug Abivertinib, clinical stage candidate AC0058...Abivertinib has the potential to improve outcomes in resistant prostate cancer, systemic lupus erythematosus...It is currently being studied as a Phase 2 treatment for COVID-19-induced respiratory compromise in the US and Brazil. A second clinical candidate, AC0058, is a next generation BTK inhibitor, currently in a Phase 1b trial for Lupus patients in the US...This facility has successfully manufactured multiple batches of the active pharmaceutical ingredient (API) and final product in capsules for Abivertinib and AC0058 for clinical studies....The merger is expected to close in the second quarter of 2021, subject to customary closing conditions and regulatory approval."

M&A • Trial status • Immunology • Infectious Disease • Lupus • Novel Coronavirus Disease • Systemic Lupus Erythematosus

Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - P1b; N=32; Recruiting; Sponsor: ACEA Therapeutics, Inc.

Clinical • New P1 trial